This is a multicenter, open-label, single-arm Phase I clinical trial to evaluate the safety and tolerability of Inaticabtagene Autoleucel Injection treatment in autoimmune hemolytic anemia that has failed at least three lines of treatment.
Age range: 18-75 years (including 18 and 75 years), regardless of gender.
The Eastern Cancer Consortium (ECOG) performance status score is 0-2.
Previously diagnosed proliferative tumors of the lymphatic system;
Secondary AIHA caused by drugs or infections;
Pregnancy or breastfeeding;
Previously undergone organ or hematopoietic stem cell transplantation;